local_hospital

Aarhus University Hospital

Address
Palle Juul-Jensens Boulevard 99, 8200 Aarhus, Denmark

Cardiovascular Diseases and Nervous System Diseases

At Aarhus University Hospital, clinical research in these therapeutic areas focuses on the link between cardiovascular health and neurological injury, with a strong emphasis on conditions that affect blood flow to the brain.

  • Ischemic stroke is the main disease under study, reflecting interest in improving outcomes after disrupted cerebral circulation.
  • Trials are exploring whether new treatments can support recovery and reduce complications in the acute phase of stroke.
  • Research also aims to better understand how therapies may protect both the brain and the wider vascular system.

This work is centered on testing new treatment approaches and evaluating their safety and effectiveness for people affected by acute stroke.

Neurology Research in Acute Stroke Care

The Department of Neurology at this site is conducting clinical trials that concentrate on urgent treatment needs in ischemic stroke, with the goal of improving care during the earliest and most critical stage of illness.

  • Research is directed at identifying therapies that may improve neurological recovery after stroke.
  • Studies are also assessing whether a new intervention can be safely used soon after the event.
  • The overall focus is on advancing treatment options for patients with acute brain ischemia.

One example is the ASSET Trial, which is examining whether semaglutide may be helpful in the acute phase after stroke.

Stroke Treatment Innovation

Clinical trial activity at Aarhus University Hospital includes research into new ways to manage acute ischemic stroke, combining expertise in neurology and vascular disease.

  • The main disease focus is ischemic stroke, a major cause of disability and long-term neurological impairment.
  • Trials are designed to test whether emerging therapies can improve patient outcomes after stroke.
  • There is also interest in understanding the broader role of metabolic and cardiovascular treatments in brain recovery.

These studies are intended to support better treatment decisions and expand the options available for patients in the acute setting.

Site Overview

assignment
352
connected trials
corporate_fare
136
sponsors
science
554
IMPs

Activity Indicator

Last 6 months

20
Trials started
+5% vs previous period.
19
Trials started 6–12 months ago
352
Total trials linked
Highly Active
trending_upGrowing+5%
5
2
3
2
5
3
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 29 therapeutic areas and 15 of 554 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 529 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
165
Sponsors (total)
136
Active sponsors
84

Sponsor Network

Top 84 by active trials.

lock +83 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +55 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 111 other sites in Denmark

description
Trial volume
352
Outperforms 98% of sites
public
Therapeutic diversity
29areas
Outperforms 95% of sites
groups
Sponsor diversity
136sponsors
Outperforms 98% of sites

Therapeutic Area Benchmark — Denmark

Select a therapeutic area to compare against other sites in Denmark.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Denmark

Market Share

Country: Denmark

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Aarhus University Hospital

lock Showing 1 of 352 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Double-Blind, Randomized, Placebo-Controlled Trial of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) Using CardioMEMS™ HF SystemRegion HovedstadenPhase IIINot RecruitingDec 2024Mar 2026

IMP list

lock Showing 1 of 554 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Dexamethasone15Unknown2017-10-022026-07-28

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.